Most Read Articles
2 years ago
Catecholamines may regulate serum HDL cholesterol level, abdominal visceral and subcutaneous fat mass in men with pheochromocytoma, based on a cross-sectional and longitudinal follow-up study.
6 days ago
There is a growing number of targeted therapies being approved for use in cancer therapy in the home setting, and this poses a potential risk among family member and caregivers, particularly those of reproductive risk age, a recent study suggests.
2 years ago

Advanced endoscopic devices can significantly improve the detection rates of colorectal polyps and tumors beyond standard colonoscopy, which has a miss rate of about 25 percent, reported speakers at the “Inventor’s Corner” session of the conference.

Christina Lau, 3 years ago

In patients with metastatic breast cancer who failed to clear circulating tumor cells (CTCs) after one cycle of first-line chemotherapy, switching to a different chemotherapy does not improve survival or delay progression, the phase III SWOG S0500 trial has shown.    

Blood type tied to prognosis in hepatocellular carcinoma

9 days ago

Blood type is associated with prognosis in Chinese hepatocellular carcinoma (HCC) patients, a new study reveals. Those with non-O blood types particularly have poorer overall survival (OS).

Over a median follow-up of 36 (25 to 75) months, 392 of the 691 HCC patients who received hepatectomy died. The 3- and 5-year survival rates were 52.9 and 38.7 percent, respectively.

Blood group was significantly associated with OS (p=0.001). The median OS for blood type O was 55 (95 percent CI, 42.69 to 67.31) months, type A 39 (32.20 to 45.80) months, type B 34 (26.58 to 41.42) months and type AB 34 (24.09 to 43.91) months.

Because the 1-, 3- and 5-year OS values for the blood type O group (88.2, 58.8 and 47.3 percent, respectively) were significantly higher than the type A/B/AB groups, which had comparable OS values (p=0.226), the study cohort was divided into O vs non-O blood type groups.

The resulting median OS for the blood type O group was 55 (42.69 to 67.30) months vs 36 (31.18 to 40.81) months for the non-O blood type group. Patients with blood type O had significantly better survival than those with non-O blood types (1-year OS, 88.2 vs 83.4 percent; 3-year OS, 58.5 vs 49.1 percent; 5-year OS, 47.3 vs 30.5 percent; p<0.001 for all).

Multivariate Cox regression analysis revealed that blood types A (hazard ratio [HR], 1.416; 95 percent CI, 1.101 to 1.820; p=0.007), B (HR, 1.736; 1.333 to 2.262; p<0.001) and AB (HR, 1.739; 1.210 to 2.499; p=0.006) were significant poor prognostic factors for HCC following hepatectomy.

The non-O blood type group (HR, 1.485; 1.204 to 1.830; p<0.001) had significantly worse OS compared with the O blood type group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
2 years ago
Catecholamines may regulate serum HDL cholesterol level, abdominal visceral and subcutaneous fat mass in men with pheochromocytoma, based on a cross-sectional and longitudinal follow-up study.
6 days ago
There is a growing number of targeted therapies being approved for use in cancer therapy in the home setting, and this poses a potential risk among family member and caregivers, particularly those of reproductive risk age, a recent study suggests.
2 years ago

Advanced endoscopic devices can significantly improve the detection rates of colorectal polyps and tumors beyond standard colonoscopy, which has a miss rate of about 25 percent, reported speakers at the “Inventor’s Corner” session of the conference.

Christina Lau, 3 years ago

In patients with metastatic breast cancer who failed to clear circulating tumor cells (CTCs) after one cycle of first-line chemotherapy, switching to a different chemotherapy does not improve survival or delay progression, the phase III SWOG S0500 trial has shown.